Risankizumab

• A Phase 4 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Pso… Pending
  2025-521424-30-00 Phase IV 1 country Icr Medical S.L.
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 Phase III 13 countries Janssen Cilag International
• A Study to Assess the Adverse Events, Effectiveness, and How the Drug Moves through the Body of Intravenous and Subcutaneous Injections of R… Recruiting
  2024-514695-41-00 Phase III 6 countries AbbVie Deutschland GmbH & Co. KG
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis… Recruiting
  2022-502050-14-00 Phase III 10 countries Abbvie Deutschland GmbH & Co. KG
• Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis Recruiting
  2023-506026-36-00 Phase III 5 countries AbbVie Deutschland GmbH & Co. KG
• Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory… Recruiting
  2025-521420-30-00 Phase I/II 1 country Universitair Medisch Centrum Groningen
• A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting
  2024-519291-11-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting
  2024-516219-25-00 Phase III 7 countries MoonLake Immunotherapeutics AG
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 Phase II 23 countries AbbVie Deutschland GmbH & Co. KG
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 Phase IV 8 countries Alimentiv Inc.
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting
  2022-500408-22-00 Phase III 3 countries Abbvie Deutschland GmbH & Co. KG
• Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting
  2022-500311-39-00 Phase IV 2 countries UZ Leuven
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended
  2024-518998-33-00 Phase III 20 countries AbbVie Deutschland GmbH & Co. KG
• Crohn's Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease Ended
  2024-516023-13-00 Phase III 4 countries AbbVie Deutschland GmbH & Co. KG
• Effects of IL-23 inhibition in patients with very early axial spondyloarthritis – evidence for a true disease modification? Ended
  2023-507718-28-00 Phase II 1 country St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
• A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended
  2024-511738-11-00 Phase III 6 countries UCB Biopharma
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended
  2022-501645-70-00 Phase III 14 countries Abbvie Deutschland GmbH & Co. KG
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended
  2023-505477-33-00 Phase III 10 countries AbbVie Deutschland GmbH & Co. KG
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended
  2023-505478-14-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended
  2023-506994-36-00 Phase III 19 countries AbbVie Deutschland GmbH & Co. KG
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended
  2023-506399-28-00 Phase III 22 countries AbbVie Deutschland GmbH & Co. KG
• Investigating the safety, feasibility, and optimal dose of risankizumab-800CW in IBD - NAVIGATE study Ended
  2024-515358-25-00 Phase I (FiH) 1 country Universitair Medisch Centrum Groningen
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment… Ended
  2023-509738-20-00 Phase IV 7 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–24 of 25 trials